NCT07445984 Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)
| NCT ID | NCT07445984 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Azienda Ospedaliero-Universitaria di Parma |
| Condition | Chronic Leukemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2021-07-28 |
| Primary Completion | 2026-07-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 250 participants in total. It began in 2021-07-28 with a primary completion date of 2026-07-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study will be conducted retrospectively and prospectively, using bone marrow (BM) or peripheral blood (PB) samples or biopsies of lymph nodes or tissues with metastatic involvement taken from previously stored samples here at the University Hospital of Parma or taken from patients that need to underwent diagnostic evaluation for a suspect or a defined diagnosis of hematological malignancies collected at the University Hospital of Parma.
Eligibility Criteria
Inclusion Criteria: * Patient aged \>1 year old, referred for evaluation to the University Hospital of Parma; * Retrospective study: previously patients with hematological malignancies; * Prospective study: 1) patients with clinical suspect of hematological malignancies which requires a diagnostic assessment using peripheral blood drawn, bone marrow aspirate/biopsy, lymph nodes biopsies or biopsies of tissues with metastatic involvement including liquor from rachicentesis, tissue aspirate etc. 2) patients with clinical suspect of relapsed/refractory onco-hematological disorder, which requires a diagnostic assessment using bone marrow aspirate/biopsy or biopsies of tissues with metastatic involvement including lymph nodes, liquor from rachicentesis, tissue aspirate etc. 3) patients that progress in blastic transformation from a chronic condition or suspect of relapsed/refractory hematological disease, which requires a diagnostic assessment using peripheral blood drawn, bone marrow aspirate/biopsy, lymph nodes biopsies or biopsies of tissues with metastatic involvement including liquor from rachicentesis, tissue aspirate etc; * Written informed consent. Retrospective study: informed consent will be signed during the first follow-up visit. Exclusion Criteria: * Age \<1 year old * Patients who are unable to provide informed consent prior to any procedure for any reason.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07445984 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, studying Chronic Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07445984 currently recruiting?
Yes, NCT07445984 is actively recruiting participants. Contact the research team at giovanni.roti@unipr.it for enrollment information.
Where is the NCT07445984 trial being conducted?
This trial is being conducted at Parma, Italy.
Who is sponsoring the NCT07445984 clinical trial?
NCT07445984 is sponsored by Azienda Ospedaliero-Universitaria di Parma. The trial plans to enroll 250 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.